Company’s first prototype product—a lightweight, wearable robotic ankle assist device—is designed to grow with the patient, an innovation that meets a specific market needContinue reading
Author Archive: AZBio
SenesTech Announces Successful Completion of a Long Term Agricultural Deployment of ContraPest®
PHOENIX, March 18, 2021 /PRNewswire/ — SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary, next generation technologies for managing animal pest populations through fertility control, today announced the conclusion of agricultural deployments of ContraPest® with demonstrated, sustained success in reducing rat populations and improving operating economies in poultry settings.Continue reading
UArizona College of Pharmacy Receives Gift to Support Students in Dual Pharmacy-Nursing Degree Program
The University of Arizona College of Pharmacy has been awarded a $1.4 million grant from the Flinn Foundation.Continue reading
Virtual Student Industry Networking Event Connects Trainees with Arizona Industry Bioscience Leaders for Thirteenth Year
The annual Student Industry Networking Event is co-hosted by the BIO5 Institute and the Bioindustry Organization of Southern Arizona (BIOSA).
New study highlights first infection of human cells during spaceflight
Astronauts face many challenges to their health, due to the exceptional conditions of spaceflight. Among these are a variety of infectious microbes that can attack their suppressed immune systems.Continue reading
TGen seeks help from Arizona dog and cat owners for COVID-19 study
Project builds on ‘One Health’ testing and disease surveillance collaborations in ArizonaContinue reading
First Patient Treated in Ivy Brain Tumor Center’s Phase 0 Clinical Trial of Pamiparib in Newly Diagnosed and Recurrent Glioblastoma
Study designed to rapidly assess drug’s ability to penetrate the blood-brain barrier in humansContinue reading
Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for targeted treatment with LORBRENA (lorlatinib)
- About 235,000 people in the US will be diagnosed with lung cancer in 2021, with non-small cell lung cancer (NSCLC) accounting for 84 percent of all lung cancers1
- ALK — anaplastic lymphoma kinase — is an important biomarker found in NSCLC, and targeted therapies have been shown to dramatically improve progression-free survival compared to the previous standard of care2,3,4
- The VENTANA ALK (D5F3) CDx Assay5 is now FDA approved as a companion diagnostic in four targeted treatments, providing more options to lung cancer patients
Castle Biosciences Launches DecisionDx-Melanoma Integrated Test Result Utilizing Artificial Intelligence to Predict Individualized Risk
Newly validated i31-GEP algorithm integrates DecisionDx-Melanoma continuous score with clinicopathologic factors designed to provide a more precise, personalized likelihood of sentinel lymph node positivity
NIH starting enrollment for third trial of blood clotting treatments for COVID-19
The National Institutes of Health has launched the last of three Phase 3 clinical trials to evaluate the safety and effectiveness of blood thinners to prevent life-threatening blood clots in adults diagnosed with COVID-19. The first patient in the trial was enrolled on February 15.